1 unchanged sentence
Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements.
−Removed: During the quarter ended June 30, 2025, n o n e of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
+Added: During the quarter ended September 30, 2025, n o n e of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.
6 unchanged sentences
001-37581), filed with the SEC on June 24, 2020).
−Removed: Aclaris Therapeutics, Inc.
−Removed: 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-37581), filed with the SEC on June 5, 2025 ).
−Removed: Form of Stock Option Grant Notice and Option Agreement used in connection with the Aclaris Therapeutics, Inc.
−Removed: 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-37581), filed with the SEC on June 5, 2025).
−Removed: Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc.
−Removed: 2025 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-37581), filed with the SEC on June 5, 2025 ).
−Removed: Employment Agreement, dated as of April 28, 2025, by and between the Registrant and Jesse Hall (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No.
−Removed: 001-37581), filed with the SEC on May 8, 2025).
−Removed: Tenth Amended and Restated Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q (File No.
−Removed: 001-37581), filed with the SEC on May 8, 2025).
+Added: Employment Agreement, effective as of July 28, 2025, by and between the Registrant and Roland Kolbeck.
Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.
14 unchanged sentences
ACLARIS THERAPEUTICS, INC.
−Removed: August 7, 2025
+Added: November 6, 2025
/s/ Neal Walker
1 unchanged sentence
(On behalf of the Registrant)
−Removed: August 7, 2025
+Added: November 6, 2025
/s/ Kevin Balthaser
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.